SCOPUS 정보 검색 플랫폼

Expert Opinion on Therapeutic Targets

Volumn 15, Issue 3, 2011, Pages 351-353

Crizotinib for EML4-ALK positive lung adenocarcinoma: A hope for the advanced disease?

(1) Antoniu, Sabina Antonela a

a GRIGORE T POPA UNIVERSITY OF MEDICINE AND PHARMACY (Romania)

Author keywords

ALK mutations; Crizotinib; EGFR mutations; NSCLC

Indexed keywords

3 [1 (2,6 DICHLORO 3 FLUOROPHENYL)ETHOXY] 5 [1 (4 PIPERIDINYL) 1H PYRAZOL 4 YL] 2 PYRIDINYLAMINE; AMINOTRANSFERASE; ANAPLASTIC LYMPHOMA KINASE; ANTINEOPLASTIC AGENT; PROTEIN TYROSINE KINASE INHIBITOR;

AMINOTRANSFERASE BLOOD LEVEL; AREA UNDER THE CURVE; ARTICLE; CANCER THERAPY; DIARRHEA; DRUG DOSE ESCALATION; DRUG HALF LIFE; DRUG SAFETY; GENE MUTATION; HUMAN; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; PHASE 1 CLINICAL TRIAL; SIDE EFFECT; TREATMENT DURATION; TREATMENT RESPONSE;

EID: 79951644556 PISSN: 14728222 EISSN: None Source Type: Journal
DOI: 10.1517/14728222.2011.550880 Document Type: Article

Times cited : (22)

References (7)

1
- 77953291664
- The biology and treatment of EML4-ALK non-small cell lung cancer
- Sasaki T, Rodig SJ, Chirieac LR, Janne PA. The biology and treatment of EML4-ALK non-small cell lung cancer. Eur J Cancer 2010;46(10):1773-80
- (2010) Eur. J. Cancer , vol.46 , Issue.10 , pp. 1773-1780
- Sasaki, T.¹ Rodig, S.J.² Chirieac, L.R.³ Janne, P.A.⁴

2
- 44849126091
- Genomic alterations of anaplastic lymphoma kinase may sensitize tumors to anaplastic lymphoma kinase inhibitors
- McDermott U, Iafrate AJ, Gray NS, et al. Genomic alterations of anaplastic lymphoma kinase may sensitize tumors to anaplastic lymphoma kinase inhibitors. Cancer Res 2008;68(9):3389-95
- (2008) Cancer Res. , vol.68 , Issue.9 , pp. 3389-3395
- McDermott, U.¹ Iafrate, A.J.² Gray, N.S.³

3
- 78049425319
- Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer
- Kwak EL, Bang YJ, Camidge DR, et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 2010;363(18):1693-703
- (2010) N Engl. J. Med. , vol.363 , Issue.18 , pp. 1693-1703
- Kwak, E.L.¹ Bang, Y.J.² Camidge, D.R.³

4
- 70350140489
- Clinical activity observed in a phase I dose escalation trial of an oral c-met and ALK inhibitor PF-02341066
- abstract 3509
- Kwak EL, Camidge DR, Clark J, et al. Clinical activity observed in a phase I dose escalation trial of an oral c-met and ALK inhibitor, PF-02341066. J Clin Oncol (Meeting Abstracts) 2009;27(15S):abstract 3509
- (2009) J. Clin. Oncol. Meeting Abstracts , vol.27
- Kwak, E.L.¹ Camidge, D.R.² Clark, J.³

5
- 69949162760
- Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma
- Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009;361(10):947-57
- (2009) N Engl. J. Med. , vol.361 , Issue.10 , pp. 947-957
- Mok, T.S.¹ Wu, Y.L.² Thongprasert, S.³

6
- 34547638047
- Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer
- DOI 10.1038/nature05945, PII NATURE05945
- Soda M, Choi YL, Enomoto M, et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 2007;448(7153):561-6 (Pubitemid 47206930)
- (2007) Nature , vol.448 , Issue.7153 , pp. 561-566
- Soda, M.¹ Choi, Y.L.² Enomoto, M.³ Takada, S.⁴ Yamashita, Y.⁵ Ishikawa, S.⁶ Fujiwara, S.-I.⁷ Watanabe, H.⁸ Kurashina, K.⁹ Hatanaka, H.¹⁰ Bando, M.¹¹ Ohno, S.¹² Ishikawa, Y.¹³ Aburatani, H.¹⁴ Niki, T.¹⁵ Sohara, Y.¹⁶ Sugiyama, Y.¹⁷ Mano, H.¹⁸

7
- 58149382583
- A mouse model for EML4-ALK-positive lung cancer
- USA
- Soda M, Takada S, Takeuchi K, et al. A mouse model for EML4-ALK-positive lung cancer. Proc Natl Acad Sci USA 2008;105(50):19893-7
- (2008) Proc. Natl. Acad. Sci. , vol.105 , Issue.50 , pp. 19893-19897
- Soda, M.¹ Takada, S.² Takeuchi, K.³

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.